FY2025 Earnings Forecast for CGTX Issued By Brookline Cap M

Cognition Therapeutics, Inc. (NASDAQ:CGTX) – Analysts at Brookline Cap M issued their FY2025 EPS estimates for shares of Cognition Therapeutics in a research note issued to investors on Tuesday, February 3rd. Brookline Cap M analyst F. Ahmed anticipates that the company will post earnings per share of ($0.35) for the year. Brookline Cap M has a “Strong-Buy” rating on the stock. The consensus estimate for Cognition Therapeutics’ current full-year earnings is ($0.80) per share. Brookline Cap M also issued estimates for Cognition Therapeutics’ Q4 2025 earnings at ($0.06) EPS, Q1 2026 earnings at ($0.07) EPS, Q2 2026 earnings at ($0.06) EPS, Q3 2026 earnings at ($0.07) EPS, Q4 2026 earnings at ($0.26) EPS and FY2026 earnings at ($0.46) EPS.

Cognition Therapeutics (NASDAQ:CGTX) last posted its quarterly earnings results on Thursday, November 6th. The company reported ($0.06) earnings per share for the quarter, topping the consensus estimate of ($0.07) by $0.01.

CGTX has been the subject of a number of other reports. B. Riley Financial restated a “buy” rating and set a $3.00 price objective (up from $2.00) on shares of Cognition Therapeutics in a research note on Friday, November 21st. Brookline Capital Acquisition raised shares of Cognition Therapeutics to a “strong-buy” rating in a research report on Tuesday. Wall Street Zen upgraded shares of Cognition Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, November 8th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Cognition Therapeutics in a research report on Monday, December 29th. Finally, HC Wainwright reissued a “buy” rating and issued a $3.00 target price on shares of Cognition Therapeutics in a report on Thursday, December 4th. Two analysts have rated the stock with a Strong Buy rating, three have given a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $3.33.

Cognition Therapeutics Trading Up 6.0%

NASDAQ CGTX opened at $1.06 on Friday. Cognition Therapeutics has a 12 month low of $0.22 and a 12 month high of $3.83. The stock’s fifty day moving average price is $1.44 and its 200-day moving average price is $1.56. The stock has a market cap of $93.57 million, a P/E ratio of -2.21 and a beta of 1.25.

Hedge Funds Weigh In On Cognition Therapeutics

Several institutional investors have recently made changes to their positions in the business. DAVENPORT & Co LLC bought a new stake in Cognition Therapeutics during the third quarter valued at approximately $3,631,000. GSA Capital Partners LLP purchased a new position in shares of Cognition Therapeutics during the 3rd quarter worth $265,000. Chescapmanager LLC grew its position in shares of Cognition Therapeutics by 98.1% during the 3rd quarter. Chescapmanager LLC now owns 997,029 shares of the company’s stock valued at $1,346,000 after acquiring an additional 493,770 shares during the period. CM Management LLC purchased a new stake in shares of Cognition Therapeutics in the 4th quarter worth $270,000. Finally, Sigma Planning Corp increased its stake in shares of Cognition Therapeutics by 70.1% in the 4th quarter. Sigma Planning Corp now owns 216,165 shares of the company’s stock worth $295,000 after purchasing an additional 89,075 shares in the last quarter. Institutional investors own 43.35% of the company’s stock.

Key Cognition Therapeutics News

Here are the key news stories impacting Cognition Therapeutics this week:

• Positive Sentiment: Brookline Capital Management upgraded CGTX to “Strong‑Buy” and released a set of quarterly and full‑year EPS estimates that are less negative than market consensus (Brookline FY2026: -$0.46 vs. consensus -$0.80). The upgrade plus narrower loss estimates likely improved investor expectations for future valuation and financing needs. Brookline coverage (MarketBeat)
• Positive Sentiment: Cognition extended the duration of its expanded access program (EAP) for Zervimesine (CT1812) in dementia with Lewy bodies, allowing enrolled patients additional months of treatment — a sign of ongoing clinical engagement and potential real‑world data generation that can de‑risk the program incrementally. GlobeNewswire: EAP extension
• Neutral Sentiment: Multiple Brookline research notes repeated the same forward‑looking quarterly estimates (Q4‑2025 through Q4‑2026) and the Strong‑Buy call — the breadth of published estimates helps set expectations but adds little new detail beyond the upgrade. Brookline coverage (MarketBeat)
• Negative Sentiment: Despite the more favorable forecasts from Brookline, Cognition remains a clinical‑stage company with no approved products and ongoing projected losses (consensus FY current year ~ -$0.80 EPS). That keeps the stock exposed to clinical, regulatory and financing risk, which can drive volatility and dilution. Market context (MarketBeat)

Cognition Therapeutics Company Profile

Cognition Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing disease-modifying therapies for neurodegenerative disorders, with an emphasis on Alzheimer’s disease. The company’s lead investigational candidate, CT1812, is an oral small molecule that antagonizes the sigma-2 receptor complex to protect synapses from amyloid-beta oligomer toxicity. By targeting a novel mechanism of action, Cognition Therapeutics aims to slow or reverse cognitive decline in patients living with Alzheimer’s disease.

CT1812 has successfully completed Phase 1 safety studies and preliminary Phase 2a trials, and is currently being evaluated in multiple Phase 2 clinical studies across North America and Europe in patients with mild-to-moderate Alzheimer’s disease.